US 10,269,202 · Application 16/152,085 · Granted Apr 23, 2019
US 10,269,202
Intelligent key system
Estimated expiration
December 26, 2022
Expired 1394 days ago
Earliest effective filing
Dec 26, 2002
+ 20 years
Dec 26, 2022
PTA +0d
Dec 26, 2022
No TD
—
Final
Dec 26, 2022
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- October 4, 2018
- Earliest effective filing
- December 26, 2002
- Issue date
- April 23, 2019
- PTA
- 0 days
- Base expiry (before PTA)
- December 26, 2022
December 26, 2002 + 20 years = December 26, 2022
- Continuation of application 13/182,891, filed Jul 14, 2011
- Continuation-in-part of application 12/261,843, filed Oct 30, 2008
- Continuation of application 11/185,110, filed Jul 20, 2005
- Continuation-in-part of application 11/010,661, filed Dec 13, 2004, issued as US 7,373,352
- Continuation-in-part of application 10/838,449, filed May 4, 2004, issued as US 7,821,395
- Continuation-in-part of application 10/329,626, filed Dec 26, 2002, issued as US 6,900,720
- Continuation-in-part of application 10/329,626, filed Dec 26, 2002, issued as US 6,900,720
- Continuation-in-part of application 11/010,661, filed Dec 13, 2004, issued as US 7,373,352
- Continuation-in-part of application 10/838,449, filed May 4, 2004, issued as US 7,821,395
- Continuation-in-part of application 10/329,626, filed Dec 26, 2002, issued as US 6,900,720
- Continuation of application 11/185,110, filed Jul 20, 2005
- Continuation-in-part of application 11/010,661, filed Dec 13, 2004, issued as US 7,373,352
- Continuation-in-part of application 10/838,449, filed May 4, 2004, issued as US 7,821,395
- Continuation-in-part of application 10/329,626, filed Dec 26, 2002, issued as US 6,900,720
- Continuation-in-part of application 11/111,559, filed Apr 21, 2005
- Continuation-in-part of application 11/010,661, filed Dec 13, 2004, issued as US 7,373,352
- Continuation-in-part of application 12/261,843, filed Oct 30, 2008
- Continuation of application 11/185,110, filed Jul 20, 2005
- Continuation-in-part of application 11/010,661, filed Dec 13, 2004, issued as US 7,373,352
- Continuation-in-part of application 10/838,449, filed May 4, 2004, issued as US 7,821,395
- Continuation-in-part of application 10/329,626, filed Dec 26, 2002, issued as US 6,900,720
- Continuation-in-part of application 11/111,559, filed Apr 21, 2005
- PRO60/528,831 — Provisional — not used for base term
- PRO60/528,831 — Provisional — not used for base term
- PRO60/344,221 — Provisional — not used for base term
- PRO60/344,221 — Provisional — not used for base term
- PRO60/344,221 — Provisional — not used for base term
- PRO60/528,831 — Provisional — not used for base term
- PRO60/344,221 — Provisional — not used for base term
- PRO60/528,831 — Provisional — not used for base term
- PRO60/344,221 — Provisional — not used for base term
- PRO60/528,831 — Provisional — not used for base term
- PRO60/528,831 — Provisional — not used for base term
- PRO60/344,221 — Provisional — not used for base term
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 16/152,085 · US 10,269,202
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 10,269,202: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US10269202Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.